Infinity Pharmaceuticals, Inc. (INFI)
| Previous close | 1.5300 |
| Open | 1.5200 |
| Bid | 1.4600 x 900 |
| Ask | 1.4700 x 800 |
| Day's range | 1.4100 - 1.5200 |
| 52-week range | 0.4600 - 3.8900 |
| Volume | |
| Avg. volume | 746,604 |
| Market cap | 130.792M |
| Beta (5Y monthly) | 2.00 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Infinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
CAMBRIDGE, Mass., August 09, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its second quarter 2022 financial results, unveiled new positive data from the Phase 2 MARIO-275 clinical trial, and provided a business update.
- Business Wire
Infinity Pharmaceuticals Announces the Date of Its Second Quarter 2022 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass., August 02, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, August 9th, 2022, at 4:30 pm ET to report its financial results for the second quarter of 2022.
- Business Wire
Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass., May 17, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022.
